Johnson and Johnson 2005 Annual Report Download - page 74

Download and view the complete annual report

Please find page 74 of the 2005 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 80

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80

PAGE 72 JOHNSON & JOHNSON 2005 ANNUAL REPORT
Therakos, Inc. specializes in extracorporeal immune cell therapies for the prevention and
treatment of serious immune-mediated and neoplastic diseases. Therakos’ proprietary
procedures in photopheresis are used by physicians for the palliative treatment of the skin
manifestations of cutaneous T-cell lymphoma.
Tibotec Pharmaceuticals Ltd. discovers and develops anti-retrovirals for the management
of HIV/AIDS and anti-infectives. The company currently has anti-retrovirals in clinical
development in both the non-nucleoside reverse transcriptase inhibitor and protease
inhibitor classes. TIBOZOLE™ (miconazole nitrate 10 mg) is a muco-adhesive tablet contain-
ing miconazole for once daily topical treatment of oro-pharyngeal candidiasis, the most
common opportunistic infection in people with HIV/AIDS in Africa.
Tibotec Therapeutics Division of Ortho Biotech Products, L.P. focuses on the U.S. sales and
marketing of virology products. Its first product, TMC114, a protease inhibitor used in the
treatment of HIV, is currently awaiting marketing approval from the U. S. Food and Drug
Administration.
Veridex, LLC provides cancer diagnostic products that will enable earlier disease detection
and more accurate staging, monitoring and therapeutic management of cancer patients.
The company is initially commercializing two complementary product lines: CELLSEARCH™
assays that identify, enumerate and characterize circulating tumor cells directly from a single
tube of blood; and GENESEARCH™ assays that use molecular technologies to diagnose,
stage and more accurately characterize tumors.
Virco BVBA develops and provides innovative and practical diagnostic services for the
management of HIV infection, including the VIRCO®TYPE HIV-1 and the ANTIVIROGRAM®
for HIV drug resistance testing. The company’s mission is to enhance the clinical management
of viral infections by providing advanced diagnostic tools based on pharmacogenomic
principles in order to improve patient care and quality of life.
www.tibotec.com
www.veridex.com
www.tibotectherapeutics.com
www.therakos.com
www.vircolab.com